KB
GHDX

Kimelman & Baird’s Genomic Health, Inc. GHDX Stock Holding History

Kimelman & Baird’s Portfolio GHDX Stock Details GHDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$627K Sell
9,240
-7,200
-44% -$494K 0.09% 67
2019
Q2 		$956K Buy
16,440
+200
+1% +$11.8K 0.13% 59
2019
Q1 		$1.14M Hold
16,240
– – 0.16% 59
2018
Q4 		$1.05M Sell
16,240
-1,000
-6% -$70.1K 0.16% 59
2018
Q3 		$1.21M Hold
17,240
– – 0.15% 59
2018
Q2 		$869K Buy
+17,240
New +$684K 0.11% 67
2017
Q4 		$658K Sell
19,240
-1,800
-9% -$57.4K 0.09% 71
2017
Q3 		$675K Hold
21,040
– – 0.1% 71
2017
Q2 		$685K Hold
21,040
– – 0.1% 72
2017
Q1 		$663K Buy
21,040
+1,600
+8% +$47.3K 0.1% 72
2016
Q4 		$571K Sell
19,440
-2,000
-9% -$61K 0.1% 73
2016
Q3 		$620K Hold
21,440
– – 0.11% 71
2016
Q2 		$555K Sell
21,440
-500
-2% -$13.3K 0.1% 71
2016
Q1 		$543K Buy
21,940
+500
+2% +$13.7K 0.1% 74
2015
Q4 		$755K Buy
+21,440
New +$574K 0.14% 72
2015
Q2 		$610K Sell
21,940
-9,960
-31% -$281K 0.1% 81
2015
Q1 		$975K Hold
31,900
– – 0.18% 73
2014
Q4 		$1.02M Sell
31,900
-3,900
-11% -$127K 0.18% 68
2014
Q3 		$1.01M Sell
35,800
-2,500
-7% -$69.7K 0.19% 71
2014
Q2 		$1.05M Buy
38,300
+1,400
+4% +$37.3K 0.18% 71
2014
Q1 		$972K Buy
36,900
+2,800
+8% +$80.3K 0.18% 70
2013
Q4 		$998K Sell
34,100
-1,500
-4% -$47.6K 0.19% 69
2013
Q3 		$1.09M Buy
35,600
+1,500
+4% +$50.2K 0.22% 69
2013
Q2 		$1.08M Buy
+34,100
New +$1.12M 0.23% 69

Other funds holding GHDX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Kimelman & Baird's GHDX Position: Q3 2019 in Review

Kimelman & Baird reduced its Genomic Health, Inc. (GHDX) stake by 44% in Q3 2019, selling an estimated $494K and leaving 9,240 shares worth $627K. The position accounts for 0.09% of the portfolio, ranked #67.

Kimelman & Baird first reported a position in GHDX in Q2 2013 and has held it in 24 quarters since. The position peaked at $1.21M in Q3 2018. 221 funds tracked by Wall St. Rank hold GHDX as of Q3 2019.

  • Kimelman & Baird held 9,240 shares of Genomic Health, Inc. worth $627K as of Q3 2019.
  • Kimelman & Baird sold 7,200 Genomic Health, Inc. shares in Q3 2019, an estimated $494K.
  • Genomic Health, Inc. made up 0.09% of Kimelman & Baird's portfolio in Q3 2019, its #67 holding.
  • Kimelman & Baird first reported a position in Genomic Health, Inc. in Q2 2013 and has held it in 24 quarters since.
  • Kimelman & Baird's Genomic Health, Inc. position peaked at $1.21M in Q3 2018.
  • 221 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q3 2019.

Based on Kimelman & Baird's 13F filing for Q3 2019, filed 10 Dec 2019.